Lennox-Gastault Syndrome is a severe epileptic disorder that manifests in various forms of seizures. This condition is one of the most severe epilepsies to occur in children. Unfortunately, most LGS patients do not respond well to existing pharmaceutical treatments used to medicate seizures. In many cases, it is impossible to identify the cause of LGS-related seizures, and the seizures themselves are often extremely difficult to manage. LGS may be accompanied by various behavioral and cognitive development issues, and while the condition manifests in childhood, it often continues into adulthood.
Treatment for Lennox-Gastault Syndrome
One of the most difficult aspects of treating LGS in children is the high frequency of seizures that characterizes the syndrome. LGS is also known for being resistant to antiepileptic drugs (AEDs), which can frequently result in debilitating side effects on their own. In a study that ran from January 2016 to February 2017, Dr. Saul Garza Morales researched the effectiveness of cannabis as a treatment for LGS-related seizures. The patients studied were still experiencing persistent daily seizures that were not resolved by taking three or more AEDs at a time.
RSHO 5000 cannabidiol oil was used to treat the patients in this study for a period of at least six months. The follow-up included MRI or CT scans as well as EEG studies. The results of the study showed a dramatic 50-percent decrease in the frequency of seizures among 84% of the patients. Another 17 percent of patients experienced complete management of their seizures for four or more months. A complete cessation of epileptic episodes is a rare result for any type of LGS treatment, making RSHO’s cannabidiol a promising treatment for continued study and use. Another 89 percent of patients in the study experienced additional benefits, such as improved attention, alertness or greater ease of social interaction.
100-Percent Cannabidiol and LGS Treatment
In addition to a lack of effectiveness, the greatest issue traditional LGS treatment options present is the possibility of unpleasant side effects. RSHO’s 100-percent cannabidiol oil is a highly safe and effective treatment that can be used in a pediatric context without the risk of harmful side effects. Throughout the study, no adverse side effects related to the cannabidiol were observed. This means that cannabidiol oil is not only more effective than AEDs that are commonly used to treat Lennox-Gastault Syndrome, but more convenient for pediatric patients as well. The 100-percent formulation eliminates many of the side effects associated with tetrahydrocannabinol, making RSHO oil more accessible to a wider variety of patients.
The 2017 findings support previous studies that have been conducted regarding the effectiveness of cannabidiol as a treatment for seizures and other serious conditions. The Mexican government offered exclusive permissions for RSHO-X products to be imported with a government permit. RSHO products have also received import permissions in countries such as Paraguay, Puerto Rico and Brazil for medical indications such as chronic pain, Parkinson’s disease and epilepsy. Each research study conducted to date has yielded promising results with regard to the effectiveness of these products as non-addictive treatment options for a variety of medical conditions.
Similar to the findings of the 2017 study, a study conducted by Dr. Carlos G. Aguirre Velazquez showed that CBD oil was effective when treating refractory epilepsy in pediatric patients. In fact, 17 percent of the children in the study experienced a complete cessation of epileptic seizures while another 53 percent experienced a significant reduction (over 75%) in the frequency of motor seizures.
While Lennox-Gastault Syndrome makes up less than 5 percent of pediatric epilepsies, the seizures associated with this syndrome are severe and often unmanageable. Because life-long treatment is typically necessary, it is important to find a medication that manages symptoms while remaining viable over the long term. Other AEDs can result in debilitating side effects, such as vomiting, diarrhea, nausea, drowsiness and, in rare cases, hepatic failure. These side effects make it even more difficult for LGS sufferers to lead normal childhoods. Fortunately, CBD oil presents the opportunity for these patients to experience a significant reduction in seizure frequency and severity without suffering any unpleasant side effects. As the RSHO product line continues to develop and yield positive study results, epileptic patients around the world will continue to benefit.
About the Author
Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/